Shin-Etsu Chemical to Develop a QST TM Substrate for 300-mm GaN
Shin-Etsu Chemical Co., Ltd. (TOKYO: 4063)(Head Office: Tokyo; President: Yasuhiko Saitoh; hereinafter, “Shin-Etsu Chemical”) has created a 300-mm (12-inch) QSTTM substrate, which is a substrate dedicated to GaN epitaxial growth, and recently started supplying samples.
Shin-Etsu Chemical has sold 150-mm (6-inch) and 200-mm (8-inch) QSTTM substrates and GaN on QSTTM epitaxial substrates of each diameter. Meanwhile, the company worked on further increasing the diameter in response to strong customer demand and successfully developed a 300-mm (12-inch) QSTTM substrate. GaN device manufacturers cannot benefit from increasing the diameter of materials because of the lack in large-diameter substrate suitable for GaN growth, despite the fact that they can use the existing Si production line for GaN. This 300-mm QSTTM substrate enables GaN epitaxial growth without warping or cracks, which was unattainable on Si substrates, thus significantly reducing device costs. In addition to the enhancement of facilities for 150-mm and 200-mm QSTTM substrates already in progress, Shin-Etsu Chemical will work on mass-producing 300-mm QSTTM substrates.
Since QSTTM substrates have the same coefficient of thermal expansion as that of GaN, it is possible to constrain warping and cracks of GaN epitaxial layer on QSTTM substrate of the SEMI standard thickness. This substrate material allows for high-quality and thick GaN epitaxial growth with a large diameter. Leveraging this feature, many customers are evaluating QSTTM substrates and GaN on QSTTM epitaxial substrates for power devices, high-frequency devices, and LEDs. Despite the challenging business environment, customers have entered the development phase toward practical to address the recently increasing interest in power devices, including power supplies for data centers.
The addition of the 300-mm QSTTM substrate to the lineup of the 150-mm and 200-mm can significantly accelerate the spread of GaN devices. Shin-Etsu Chemical is committed to contribute to the realization of a sustainable society where energy can be used efficiently through the social implementation of GaN devices.
Note that the company plans to exhibit this 300-mm QSTTM substrate at SEMICON TAIWAN, which will be held in Taipei, Taiwan, from September 4 to 6, 2024.
*1: The QSTTM substrate is a composite material dedicated to GaN growth developed by Qromis (CA, U.S.A, CEO: Cem Basceri) and was licensed to Shin-Etsu Chemical in 2019. QSTTM is a U.S. trademark of Qromis (registration No. 5277631).
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904211607/en/
Contacts
For inquiries about this matter, please contact:
Shin-Etsu Chemical Co., Ltd.
Public Relations Dept.
Tetsuya Koishikawa
Tel: 03-6812-2340, or from outside Japan: 81-3-6812-2340
Fax: 03-6812-2341, or from outside Japan: 81-3-6812-2341
E-mail: sec-pr@shinetsu.jp
www.shinetsu.co.jp -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.shinetsu.co
.jp&esheet=54117806&newsitemid=20240904211607&lan=en-US&anchor=www.shinetsu.co.j
p&index=1&md5=e95093d458ac92dcc64fa649bd6e194c
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeiGene Highlights TEVIMBRA ® Data in Lung and Gastrointestinal Cancers at ESMO 20249.9.2024 07:00:00 CEST | Press release
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share new data for TEVIMBRA® (tislelizumab) at the European Society of Medical Oncology 2024 Congress (ESMO 2024) in Barcelona, Spain, September 13-17, 2024. BeiGene has seven abstracts accepted at ESMO 2024, with one selected for the special session revisiting the ESMO Virtual Plenary held in February 2024. New Data Add to Evidence for TEVIMBRA Across Multiple Disease States As an encore to the ESMO plenary, interim results from the RATIONALE-315 study show the statistically significant event-free survival (EFS) and trend for overall survival (OS) benefit favoring neoadjuvant tislelizumab plus chemotherapy with adjuvant tislelizumab vs. placebo plus chemotherapy with adjuvant placebo for patients with resectable non-small cell lung cancer (NSCLC) (session #VP1-2024, Sept. 13 from 4:17-4:29 p.m. CEST). These results further reinforce the data presented at ESMO 2023 showing major p
Nytt i Personio: Bättre medarbetarinsikter och prestationsbedömningar, anpassade arbetsflöden och löneutbetalningar ökar effekten för HR-team9.9.2024 01:01:00 CEST | Pressmeddelande
Personio, Europas ledande HR-systemföretag för små och medelstora företag, har idag presenterat en rad förbättringar utformade för att minska administrationen för HR-team så att de kan fokusera mer på att leverera resultat för sina organisationer. Detta pressmeddelande använder multimedia. Se den fullständiga versionen här: https://www.businesswire.com/news/home/20240908703783/sv/ Personio releases a series of advancements to further alleviate the burden of manual and time-intensive administrative tasks for HR teams. (Photo: Business Wire) Dessa förbättringar annonseras samtidigt som lanseringen av Personios senaste undersökning, Workforce Pulse 2024: Så löser du personal- och engagemangsrelaterade utmaningar. Den visar att 32% av HR-beslutsfattarna anser att den viktigaste utmaningen som deras organisationer måste ta itu med under det kommande året är att behålla talanger. Detta följs av 29% som anser att man bör fokusera på att förbättra medarbetarnas välbefinnande och 27% som säger
Day 2 of 11 th Annual World Patient Safety, Science & Technology Summit Highlights Importance of Collaboration and Advanced Technologies8.9.2024 09:17:00 CEST | Press release
The second day of the 11th Annual World Patient Safety, Science & Technology Summit, presented by the Patient Safety Movement Foundation (PSMF) on the UC Irvine campus, underscored the theme of collaboration as essential in creating a future in which no patients are harmed by preventable medical errors and technologies continue to evolve at an accelerated pace to advance patient care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240907191633/en/ The Global Interprofessional Patient Safety Fellowship at the 2024 PSMF Summit. From left to right: Dr. Michael A.E. Ramsay, Chief Executive Officer of PSMF; Dr. Mike Durkin, Chair of PSMF and Senior Advisor on Patient Safety Policy and Leadership, Institute of Global Health Innovation, Imperial College London; Luis Torres Torija Arguelles, MD, MBA, Ambassador of PSMF, Mexico; Natalia Camargo, RN and healthcare quality management specialist, Sao Paulo, Brazil; Afifa Munawar, BScN,
Patient Safety Global Ministerial Summit Recognizes PSMF Founder Joe Kiani6.9.2024 20:41:00 CEST | Press release
Global leaders in patient safety gathered for day one of the 11th Annual World Patient Safety, Science & Technology Summit to spotlight the most critical issues affecting patient safety. Held on the UC Irvine campus for the first time, the Patient Safety Movement Foundation’s (PSMF) annual meeting aims to build on progress made over the past decade toward eliminating preventable harm caused by medical error. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240906604830/en/ Patient Safety Movement Foundation Founder Joe Kiani is recognized by the Patient Safety Global Ministerial Summit at PSMF's annual World Patient Safety, Science & Technology Summit, which opened today. Dr. Mike Durkin, PSMF's board chair, presented the honor. (Photo: Business Wire) After PSMF founder Joe Kiani provided the Summit’s opening remarks, the Patient Safety Global Ministerial Summit recognized him for his work in patient safety. “We recognize Joe
Bentley Systems Acquires 3D Geospatial Company Cesium6.9.2024 14:53:00 CEST | Press release
Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced it has acquired 3D geospatial company Cesium. Cesium is recognized as the foundational open platform for creating powerful 3D geospatial applications, and its 3D Tiles open standard has been widely adopted by leading enterprises, governments, and tens of thousands of application developers globally. Cesium ion, the company’s SaaS platform, brings 3D geospatial experiences to more than 1 million active devices every month, while Cesium's open-source offerings have more than 10 million downloads. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240906426926/en/ Example of a design review process leveraging the Cesium integration with iTwin Platform (Photo: Bentley Systems) Bentley’s iTwin Platform powers digital twin solutions that are used by engineering and construction firms and owner-operators to design, build, and o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom